Pharming Group Statistics

Total Valuation

Pharming Group has a market cap or net worth of EUR 597.29 million. The enterprise value is 557.23 million.

Market Cap	597.29M
Enterprise Value	557.23M

Important Dates

The next estimated earnings date is Friday, April 4, 2025.

Earnings Date	Apr 4, 2025
Ex-Dividend Date	n/a

Share Statistics

Pharming Group has 678.35 million shares outstanding. The number of shares has decreased by -1.41% in one year.

Current Share Class	n/a
Shares Outstanding	678.35M
Shares Change (YoY)	-1.41%
Shares Change (QoQ)	-24.96%
Owned by Insiders (%)	2.53%
Owned by Institutions (%)	10.05%
Float	656.57M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.24
PB Ratio	2.25
P/TBV Ratio	4.20
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-34.87
EV / Sales	2.17
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1,211.49

Financial Position

The company has a current ratio of 3.53, with a Debt / Equity ratio of 0.56.

Current Ratio	3.53
Quick Ratio	2.76
Debt / Equity	0.56
Debt / EBITDA	209.36
Debt / FCF	-247.73
Interest Coverage	-1.08

Financial Efficiency

Return on equity (ROE) is -8.18% and return on invested capital (ROIC) is -1.64%.

Return on Equity (ROE)	-8.18%
Return on Assets (ROA)	-1.38%
Return on Capital (ROIC)	-1.64%
Revenue Per Employee	670,678
Profits Per Employee	-41,833
Employee Count	382
Asset Turnover	0.66
Inventory Turnover	0.52

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.34% in the last 52 weeks. The beta is 0.84, so Pharming Group's price volatility has been lower than the market average.

Beta (5Y)	0.84
52-Week Price Change	-15.34%
50-Day Moving Average	0.77
200-Day Moving Average	0.80
Relative Strength Index (RSI)	65.12
Average Volume (20 Days)	8,004,665

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Pharming Group had revenue of EUR 256.20 million and -15.98 million in losses. Loss per share was -0.02.

Revenue	256.20M
Gross Profit	229.03M
Operating Income	-8.53M
Pretax Income	-15.42M
Net Income	-15.98M
EBITDA	-2.74M
EBIT	-8.53M
Loss Per Share	-0.02

Full Income Statement

Balance Sheet

The company has 154.01 million in cash and 113.94 million in debt, giving a net cash position of 40.06 million or 0.06 per share.

Cash & Cash Equivalents	154.01M
Total Debt	113.94M
Net Cash	40.06M
Net Cash Per Share	0.06
Equity (Book Value)	202.45M
Book Value Per Share	0.39
Working Capital	181.43M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 404,367 and capital expenditures -864,322, giving a free cash flow of -459,955.

Operating Cash Flow	404,367
Capital Expenditures	-864,322
Free Cash Flow	-459,955
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross margin is 89.39%, with operating and profit margins of -3.33% and -6.24%.

Gross Margin	89.39%
Operating Margin	-3.33%
Pretax Margin	-6.02%
Profit Margin	-6.24%
EBITDA Margin	-1.07%
EBIT Margin	-3.33%
FCF Margin	n/a

Dividends & Yields

Pharming Group does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	1.41%
Shareholder Yield	1.41%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on March 5, 2013. It was a reverse split with a ratio of 0.1.

Last Split Date	Mar 5, 2013
Split Type	Reverse
Split Ratio	0.1

Scores

Pharming Group has an Altman Z-Score of 2.32. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.32
Piotroski F-Score	n/a